AstraZeneca's Breztri Aerosphere Approved in the US for Asthma Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
AstraZeneca's fixed-dose triple-combination therapy Breztri Aerosphere has been approved in the US for the maintenance treatment of asthma in adult and pediatric patients 12 years of age and older. Breztri is a single-inhaler that combines the efficacy of corticosteroid/long-acting beta2-agonist medicines with a long-acting muscarinic antagonist, LAMA. Breztri was approved in the US in 2020 to treat adults with chronic obstructive pulmonary disease, COPD, and was prescribed to more than 6.8 million patients globally in 2025.1,2
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
